Equities analysts forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will report earnings per share (EPS) of ($0.22) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Tandem Diabetes Care’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.24). Tandem Diabetes Care posted earnings of ($1.23) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 82.1%. The firm is scheduled to announce its next earnings report after the market closes on Tuesday, February 26th.

According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($3.22) per share for the current fiscal year, with EPS estimates ranging from ($3.83) to ($3.04). For the next year, analysts anticipate that the firm will post earnings of ($0.77) per share, with EPS estimates ranging from ($1.18) to ($0.64). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Tandem Diabetes Care.

Several analysts recently issued reports on TNDM shares. Oppenheimer set a $57.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a report on Friday, November 2nd. BidaskClub upgraded Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 12th. Lake Street Capital set a $60.00 target price on Tandem Diabetes Care and gave the company a “buy” rating in a research note on Monday, October 15th. Robert W. Baird upgraded Tandem Diabetes Care from a “neutral” rating to an “outperform” rating and set a $46.00 target price for the company in a research note on Wednesday, November 21st. Finally, UBS Group started coverage on Tandem Diabetes Care in a research note on Tuesday, November 27th. They set a “neutral” rating and a $36.00 target price for the company. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $44.75.

In other Tandem Diabetes Care news, EVP Brian B. Hansen sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, January 15th. The shares were sold at an average price of $41.54, for a total value of $1,038,500.00. Following the transaction, the executive vice president now owns 26,381 shares of the company’s stock, valued at $1,095,866.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John F. Sheridan sold 20,000 shares of the firm’s stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $45.26, for a total transaction of $905,200.00. Following the completion of the transaction, the executive vice president now directly owns 20,666 shares in the company, valued at approximately $935,343.16. The disclosure for this sale can be found here. Insiders sold 112,281 shares of company stock valued at $4,428,597 over the last quarter. Insiders own 9.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. bought a new position in Tandem Diabetes Care in the fourth quarter worth about $44,000. IFP Advisors Inc lifted its holdings in Tandem Diabetes Care by 78.4% in the fourth quarter. IFP Advisors Inc now owns 1,757 shares of the medical device company’s stock worth $66,000 after acquiring an additional 772 shares during the last quarter. US Bancorp DE lifted its holdings in Tandem Diabetes Care by 397.8% in the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after acquiring an additional 1,989 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Tandem Diabetes Care in the third quarter worth about $109,000. Finally, Meeder Asset Management Inc. lifted its holdings in Tandem Diabetes Care by 1,921.6% in the third quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock worth $116,000 after acquiring an additional 2,575 shares during the last quarter. 72.17% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ TNDM traded up $1.37 during trading hours on Wednesday, hitting $43.66. The company had a trading volume of 30,514 shares, compared to its average volume of 1,003,399. Tandem Diabetes Care has a fifty-two week low of $2.14 and a fifty-two week high of $52.55. The company has a market cap of $2.50 billion, a P/E ratio of -3.40 and a beta of 0.49.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.